New York device maker AngioDynamics has been struggling for a while, but the company has all elements of a come-back.
Experienced investors know that the stock market is largely a forward-looking mechanism for valuing companies, and while AngioDynamics (NSDQ:ANGO) continues to struggle with very real present-day challenges, management has been making a number of steps to restore this company to attractive long-term growth and margins. Thursday's fiscal first quarter earnings served to highlight both sides of that story, as current market conditions remain difficult, but management continues to make progress on multiple fronts.
Valuing AngioDynamics today really is an exercise in your confidence that these plans will bear fruit. Today's valuation already appears relatively generous given the underlying growth rates of the markets the company serves, but if AngioDynamics is truly moving back to a position from which it gain share, a further move in the stock could be waiting.